Brokerages Set Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Price Target at $8.20

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) has been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.20.

Several brokerages have recently commented on WHWK. Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Oppenheimer reissued an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. B. Riley Financial began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings cut Whitehawk Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, June 5th. Finally, Leerink Partners began coverage on Whitehawk Therapeutics in a report on Monday, July 13th. They issued an “outperform” rating and a $9.00 target price on the stock.

Whitehawk Therapeutics Stock Performance

Shares of NASDAQ WHWK opened at $5.08 on Wednesday. The stock has a market capitalization of $289.61 million, a P/E ratio of -4.54 and a beta of 0.76. The stock’s fifty day moving average is $4.24 and its 200 day moving average is $3.95. Whitehawk Therapeutics has a 52 week low of $1.71 and a 52 week high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. Equities research analysts forecast that Whitehawk Therapeutics will post -1.1 earnings per share for the current year.

Institutional Trading of Whitehawk Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Montanova Capital LLC grew its position in Whitehawk Therapeutics by 16.2% in the second quarter. Montanova Capital LLC now owns 4,300,000 shares of the company’s stock valued at $19,694,000 after acquiring an additional 600,000 shares during the last quarter. Two Sigma Securities LLC bought a new position in shares of Whitehawk Therapeutics in the second quarter worth about $46,000. Bank of America Corp DE acquired a new stake in shares of Whitehawk Therapeutics in the 2nd quarter valued at approximately $159,000. ADAR1 Capital Management LLC acquired a new stake in shares of Whitehawk Therapeutics in the 2nd quarter valued at approximately $6,144,000. Finally, BlackRock Inc. bought a new stake in shares of Whitehawk Therapeutics during the 2nd quarter valued at approximately $8,807,000. 52.08% of the stock is currently owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.